SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

Attention centers on CRISPR Therapeutics CTX310 clinical data and other pipeline readouts, with traders debating whether encouraging results can shift sentiment toward its in-vivo gene-editing and autoimmune programs. Optimism about the catalysts and Casgevys commercial ramp is tempered by frustration that the stock has remained range-bound and may not respond to positive developments.

Starbucks Corp. engages in the production, marketing, and retailing of specialty coffee. It operates through the following segments: North America, International, and Channel Development. The North America segment focuses on the United States and Canada. The International segment is involved in China, Japan, Asia Pacific, Europe, Middle East, Africa, Latin America, and Caribbean. The Channel Development segment includes roasted whole bean and ground coffees, Seattle’s Best Coffee, and Teavana-branded single-serve products. The company was founded by Jerry Baldwin and Howard D. Schultz on November 4, 1985, and is headquartered in Seattle, WA.

Starbucks Corp.

Starbucks Corp

Starbucks quarterly results sparked debate after stronger-than-expected earnings and comparable sales were offset by a revenue miss, with the China restructuring weighing on reported sales and the stocks reaction remaining subdued. Bulls point to improving U.S. traffic and the turnaround outlook, while bears question the valuation and whether growth can justify it.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCath reimbursement could decline sharply through 2027 has weighed on CRMD, intensifying concerns about pricing and revenue from its flagship product. Traders disagree on how decisive the warning is: some view DaVitas estimates as preliminary and point to CMS reimbursement and adoption as offsets, while others see lasting pressure on the business outlook.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Takeover speculation has fueled attention after reports that Lundbeck explored acquiring Xeris, though the company said it is not for sale and traders disagree on whether a deal is likely. The discussion also centers on upcoming quarterly results and the longer-term potential of Recorlev growth and XP-8121s planned Phase 3 program.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Ciscos decline is being tied to an analyst price-target cut amid concerns that networking growth may be peaking and the stocks valuation could compress; the firm kept its rating unchanged. Traders are split between calling the selloff an overreaction given AI-networking demand and seeing continued technical weakness.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Traders are split on Disneys choppy, range-bound trading, with bullish breakout and call-positioning talk countered by bearish bets on a pullback. Some posts also react negatively to allegations involving the company, but the discussion does not establish them as a confirmed market catalyst.

BNB (BNB) is a cryptocurrency . BNB has a current supply of 131,511,387.69. The last known price of BNB is 703.59425696 USD and is up 0.47 over the last 24 hours. It is currently trading on 3523 active market(s) with $2,735,089,335.64 traded over the last 24 hours. More information can be found at https://bnbchain.org/en.

Binance

A reported multibillion-dollar Binance security breach is driving attention, with traders focused on suspended withdrawals and concerns about exchange security and customer funds. The community debates whether Binance can cover the losses and whether BNBs limited decline understates the risk; claims of an inside job or specific perpetrators remain speculation.

Invesco Exchange-Traded Fund Trust - Invesco S&P 500 Equal Weight ETF

Invesco S&P 500 Equal Weight ETF

RSP is drawing attention as a gauge of market breadth and the rotation between mega-cap tech and the broader S&P 500: traders have highlighted periods of equal-weight outperformance as participation widens beyond AI and tech leaders. The reaction is mixed, with some viewing the rotation as healthy broadening and others warning that recent RSP weakness signals deteriorating breadth and renewed concentration in a few large stocks.

Pudgy Penguins (PENGU) is a cryptocurrency launched in 2024and operates on the Solana platform. Pudgy Penguins has a current supply of 76,724,221,264.3 with 62,860,396,090.04 in circulation. The last known price of Pudgy Penguins is 0.00754361 USD and is up 6.59 over the last 24 hours. It is currently trading on 540 active market(s) with $130,377,930.32 traded over the last 24 hours. More information can be found at https://www.pengu.pudgypenguins.com.

Pudgy Penguins

PENGU is drawing attention around its pullback and attempts to hold a technical support zone, with traders debating whether it can rebound or break lower. Dip buyers point to possible support and broader crypto-market recovery, while bears cite persistent selling, weak momentum and a lack of fresh catalysts.

Barrick Mining Corp. engages in the production and sale of gold, copper, and related activities. It also provides exploration and mining development. It operates through the following business segments: Carlin, Cortez, Turquoise Ridge, Pueblo Viejo, Loulo-Gounkoto, Kibali, Veladero, North Mara, Bulyanhulu, and Other Mines. The company was founded by Peter D. Munk in 1983 and is headquartered in Toronto, Canada.

Barrick Mining Corp.

Barrick Mining Corp

Barrick is drawing attention as its shares and the wider mining sector face pressure, with repeated technical analysis suggesting the correction may not be over. Traders are divided between expecting further weakness and treating the pullback as an opportunity to add, while gold-price and interest-rate concerns weigh on near-term sentiment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

FibroBiologics Presents Preclinical Data on Fibroblast Spheroid-Derived Chondrocyte Spheroids for Degenerative Disc Disease at the North American Spine Society 2026 Annual Meeting

FibroBiologics Presents Preclinical Data on Fibroblast Spheroid-Derived Chondrocyte Spheroids for Degenerative Disc Disease at the North American Spine Society 2026 Annual Meeting FibroBiologics Presents Preclinical Data on Fibroblast Spheroid-Derived Chondrocyte Spheroids for Degenerative Disc...

FibroBiologics Announces Australian Patent Accepted for Cellular Blend for the Regeneration of Chondrocytes and Cartilage Cells in Degenerated Spinal Discs

FibroBiologics Announces Australian Patent Accepted for Cellular Blend for the Regeneration of Chondrocytes and Cartilage Cells in Degenerated Spinal Discs FibroBiologics Announces Australian Patent Accepted for Cellular Blend for the Regeneration of Chondrocytes and Cartilage Cells in Degenerated...

FibroBiologics Files Patent Application for Technology Designed to Produce GLP-1 and Other Therapeutic Peptides Inside the Body

FibroBiologics Files Patent Application for Technology Designed to Produce GLP-1 and Other Therapeutic Peptides Inside the Body FibroBiologics Files Patent Application for Technology Designed to Produce GLP-1 and Other Therapeutic Peptides Inside the BodyPR NewswireHOUSTON, Oct. 7, 2026New approach...

FibroBiologics Announces Grant of European Patent for Methods of Enhancing Fibroblast Therapeutic Activity

FibroBiologics Announces Grant of European Patent for Methods of Enhancing Fibroblast Therapeutic Activity FibroBiologics Announces Grant of European Patent for Methods of Enhancing Fibroblast Therapeutic ActivityPR NewswireHOUSTON, Sept. 29, 2026 Newly Granted Patent Covers Methods of Augmenting...

FibroBiologics Announces Closing of $0.5 Million Private Placement with Chief Scientific Officer

FibroBiologics Announces Closing of $0.5 Million Private Placement with Chief Scientific Officer FibroBiologics Announces Closing of $0.5 Million Private Placement with Chief Scientific OfficerPR NewswireHOUSTON, Sept. 17, 2026 HOUSTON, Sept. 17, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq...

FibroBiologics Announces Issuance of New U.S. Patent for the Therapeutic Use of Fibroblasts in Wound Healing

FibroBiologics Announces Issuance of New U.S. Patent for the Therapeutic Use of Fibroblasts in Wound Healing FibroBiologics Announces Issuance of New U.S. Patent for the Therapeutic Use of Fibroblasts in Wound Healing PR Newswire HOUSTON, Sept. 3, 2026 Newly Issued Patent Covers Topical...

FibroBiologics Announces Issuance of New U.S. Patent for the Treatment of Degenerative Disc Disease Using Fibroblast Conditioned Media

FibroBiologics Announces Issuance of New U.S. Patent for the Treatment of Degenerative Disc Disease Using Fibroblast Conditioned Media FibroBiologics Announces Issuance of New U.S. Patent for the Treatment of Degenerative Disc Disease Using Fibroblast Conditioned Media PR Newswire HOUSTON, Sept. 1...

FibroBiologics Releases Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial

FibroBiologics Releases Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial FibroBiologics Releases Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial PR Newswire HOUSTON, Aug. 27, 2026 HOUSTON, Aug. 27, 2026 /PRNewswire...

FibroBiologics Regains Compliance with Nasdaq Trading Rules

FibroBiologics Regains Compliance with Nasdaq Trading Rules FibroBiologics Regains Compliance with Nasdaq Trading Rules PR Newswire HOUSTON, Aug. 26, 2026 HOUSTON, Aug. 26, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology...

FibroBiologics Appoints Leigh Steinberg to Board of Directors

FibroBiologics Appoints Leigh Steinberg to Board of Directors FibroBiologics Appoints Leigh Steinberg to Board of Directors PR Newswire HOUSTON, Aug. 24, 2026 Legendary Sports Agent, Attorney, and Longtime Advocate for Human Longevity and Brain Health Joins BoardHOUSTON, Aug. 24, 2026 /PRNewswire...

FibroBiologics, Inc. engages in the development and commercialization of cell therapies. It focuses on treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. The firm’s product pipeline includes CybroCell, CYMS101, CYWC628, TCB190, and CYTER915. The company was founded by Peter O’Heeron on April 8, 2021 and is headquartered in Houston, TX.

FibroBiologics Inc

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$0.93
Prev Close	$0.9281
Open	$0.92
Dividend Yield	0.00%
50-Day Moving Average	$1.31
Beta	-0.05
Avg. Volume	243,922.61
PE Ratio	-0.16

52-Week High	$9.60
52-Week Low	$0.62
Market Capitalization	$6.19M
EPS (Annual)	-$8.35
Price to Book	1.22
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

FBLG Fundamentals